gabexate has been researched along with Influenza, Human in 3 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
Influenza, Human: An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Camostat reduced the amounts of influenza viruses in the supernatants and viral RNA in the cells." | 1.42 | The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells. ( Hatachi, Y; Homma, M; Hongo, S; Kitajima, Y; Kubo, H; Lusamba Kalonji, N; Matsuo, K; Nagatomi, R; Nishimura, H; Shimotai, Y; Tando, Y; Yamaya, M, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Stopsack, KH | 1 |
| Mucci, LA | 1 |
| Antonarakis, ES | 1 |
| Nelson, PS | 1 |
| Kantoff, PW | 1 |
| Yamaya, M | 1 |
| Shimotai, Y | 1 |
| Hatachi, Y | 1 |
| Lusamba Kalonji, N | 1 |
| Tando, Y | 1 |
| Kitajima, Y | 1 |
| Matsuo, K | 1 |
| Kubo, H | 1 |
| Nagatomi, R | 1 |
| Hongo, S | 1 |
| Homma, M | 1 |
| Nishimura, H | 1 |
| FEUILTAUT, R | 1 |
| BELCOURT, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-blind, Placebo-controlled, Multicenter, Multi-arm, Phase II Trial of Novel Agents for the Treatment of Mild to Moderate COVID-19 Positive Outpatients[NCT04530617] | Phase 2 | 246 participants (Actual) | Interventional | 2020-10-05 | Terminated (stopped due to Results from the interim analysis) | ||
| Treatment Effect of Nafamostat Mesylate in Patients With COVID-19 Pneumonia: Open Labelled Randomized Controlled Clinical Trial[NCT04418128] | Phase 2/Phase 3 | 84 participants (Anticipated) | Interventional | 2020-06-10 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for gabexate and Influenza, Human
| Article | Year |
|---|---|
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Esters; Female; Gabexate; Gene Expression Regulat | 2020 |
2 other studies available for gabexate and Influenza, Human
| Article | Year |
|---|---|
The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells.
Topics: Aged; Animals; Aprotinin; Cells, Cultured; Dogs; Epithelial Cells; Esters; Female; Gabexate; Guanidi | 2015 |
The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells.
Topics: Aged; Animals; Aprotinin; Cells, Cultured; Dogs; Epithelial Cells; Esters; Female; Gabexate; Guanidi | 2015 |
The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells.
Topics: Aged; Animals; Aprotinin; Cells, Cultured; Dogs; Epithelial Cells; Esters; Female; Gabexate; Guanidi | 2015 |
The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells.
Topics: Aged; Animals; Aprotinin; Cells, Cultured; Dogs; Epithelial Cells; Esters; Female; Gabexate; Guanidi | 2015 |
[The 1959 influenza in hospitalized military personnel in the Hopital Ste-Foy, Quebec].
Topics: Gabexate; Humans; Influenza, Human; Military Medicine; Military Personnel; Quebec | 1960 |